Paul Marks
Paul Marks · Science & Medicine
Cancer researcher who developed vorinostat, an HDAC-inhibitor anticancer drug
1926, New York City, United States — 2020, New York City, United States
United States
Paul Marks is recognized among Jewish contributors to Science & Medicine — Cancer researcher who developed vorinostat, an HDAC-inhibitor anticancer drug
Marks was a cancer researcher and long-serving president of Memorial Sloan Kettering Cancer Center. His laboratory work on cell differentiation led to the development of vorinostat (SAHA), the first histone deacetylase (HDAC) inhibitor approved as an anticancer drug, used against cutaneous T-cell lymphoma. He was Jewish, born in New York City.
Verify and go deeper with these external references.
Source: Jinfo.org — Jews in Biomedical Science
Cancer researcher who developed vorinostat, an HDAC-inhibitor anticancer drug
Source: Jinfo.org — Jews in Biomedical Science
Similar Contributors
Lawrence Einhorn
Susan Horwitz
Ronald Levy
Isaac Berenblum
Alan Bernstein
